Stanolone

Suppliers

Names

[ CAS No. ]:
521-18-6

[ Name ]:
Stanolone

[Synonym ]:
Stanolone
EINECS 208-307-3
Anaboleen
17β-Hydroxy-5α-androstane-3-one
Androlone
dihydrotestosterone
Anabolex
(5a,17b)-17-Hydroxyandrostan-3-one
5α-Dihydrotestosterone
Stanorone
5α dihydrotestosterone
Androstanolone
DHT
[14C]-Dihydrotestosterone
Androstan-3-one, 17-hydroxy-, (5α,17β)-
5α-Androstan-3-one, 17β-hydroxy-
[3H]-Dihydrotestosterone
17beta-hydroxy-5alpha-androstan-3-one
Andractim
17β-hydroxy-5α-androstan-3-one
Androstan-17b-ol-3-one
Stanaprol
4-dihydrotestosterone
Neodrol
(5α,17β)-17-Hydroxyandrostan-3-one
5a-Dihydrotestosterone
Protona
Stanolon
Anaprotin
MFCD00003667

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
413.1±38.0 °C at 760 mmHg

[ Melting Point ]:
178-183 °C

[ Molecular Formula ]:
C₁₉H₃₀O₂

[ Molecular Weight ]:
290.440

[ Flash Point ]:
176.4±19.4 °C

[ Exact Mass ]:
290.224579

[ PSA ]:
37.30000

[ LogP ]:
3.75

[ Vapour Pressure ]:
0.0±2.2 mmHg at 25°C

[ Index of Refraction ]:
1.536

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: BV8052000

CHEMICAL NAME :: 5-alpha-Androstan-3-one, 17-beta-hydroxy-

CAS REGISTRY NUMBER :: 521-18-6

LAST UPDATED :: 199206

DATA ITEMS CITED :: 19

MOLECULAR FORMULA :: C19-H30-O2

MOLECULAR WEIGHT :: 290.49

WISWESSER LINE NOTATION :: L E5 B666 OVTJ A1 E1 FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 17500 ug/kg

SEX/DURATION :: female 35 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 160 mg/kg

SEX/DURATION :: female 14-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1400 ug/kg

SEX/DURATION :: female 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 700 ug/kg

SEX/DURATION :: female 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 80 mg/kg

SEX/DURATION :: female 13-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2500 ug/kg

SEX/DURATION :: female 10 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 168 mg/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Implant

DOSE :: 24 mg/kg

SEX/DURATION :: male 42 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 150 mg/kg

SEX/DURATION :: female 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 40 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 40 mg/kg

SEX/DURATION :: female 10 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - other effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 gm/kg

SEX/DURATION :: female 14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - skin and skin appendages

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 24 mg/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 200 ug/kg

SEX/DURATION :: male 20 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 14 mg/kg

SEX/DURATION :: male 70 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Implant

DOSE :: 3420 ug/kg

SEX/DURATION :: male 90 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 30 mg/kg

SEX/DURATION :: female 1-3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 1500 ug/kg

SEX/DURATION :: female 1-3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

MUTATION DATA

TEST SYSTEM :: Non-mammalian species

DOSE/DURATION :: 12 mg/8W (Intermittent)

REFERENCE :: JEZOAO Journal of Experimental Zoology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1904- Volume(issue)/page/year: 205,403,1978

Safety Information

[ Symbol ]:

GHS02, GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H225-H301 + H311 + H331-H370

[ Precautionary Statements ]:
P210-P280-P302 + P352 + P312-P304 + P340 + P312-P370 + P378-P403 + P235

[ Personal Protective Equipment ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R61

[ Safety Phrases ]:
S53-S36/37/39-S45

[ RIDADR ]:
UN1230 - class 3 - PG 2 - Methanol, solution

[ WGK Germany ]:
3

[ RTECS ]:
BV8052000

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

17β-TBDMS-dihydrotestosterone
(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-((triethylsilyl)oxy)tetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
5a-Androstanedione
3,3-Aethylendioxy-17β-hydroxy-5α-androstan
Androstan-3-one, 17-[(2-methoxyethoxy)methoxy]-, (17β)
Testosterone
3,17β-bis-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy]-5α-androst-2-ene
(3R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl (3,5-di-tert-butyl-4-oxocyclohexa-2,5-dien-1-ylidene)azinate

DownStream

Androstan-17-ol,3,3-difluoro-, acetate, (5a,17b)- (9CI)
Epiandrosterone
Androsterone
5a-Androstanedione
5α-Androstane-3β,17β-diol
(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylspiro[1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,2'-oxirane]-17-ol
5a-Androstane-3a,17b-diol
(5S,8R,9S,10R,13S,14S)-10,13-dimethyl-5,6,7,8,9,11,12,14,15,16-decahydro-4H-cyclopenta[a]phenanthrene-3,17-dione
Androstane-3,16,17-triol,(3b,5a,16b,17b)-
5α-androstane-2β,3α,16α,17β-tetrol

Articles

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.

Cancer Res. 75(6) , 1102-12, (2015)

The translation initiation factor eIF4E is an oncogene that is commonly overexpressed in primary breast cancers and metastases. In this article, we report that a pharmacologic inhibitor of eIF4E funct...

Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface.

Biomacromolecules 16(4) , 1382-9, (2015)

Natural biomolecules are often used to functionalize materials to achieve desired cell-material interactions. However, their applications can be limited owing to denaturation during the material funct...

Co-ordinated brain and craniofacial development depend upon Patched1/XIAP regulation of cell survival.

Hum. Mol. Genet. 24(3) , 698-713, (2015)

Congenital brain and craniofacial defects often occur together as a consequence of their developmental dependency on common progenitor tissue interactions and signaling pathways during embryogenesis. ...

Stanolone-d3
Stanolone Acetate
Stanolone benzoate
Stanolone-17-bebzoate
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
N1-(2-(furan-2-yl)-2-(4-phenylpiperazin-1-yl)ethyl)-N2-(2-methoxyphenethyl)oxalamide
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
(4-Methyl-tetrahydro-furan-2-yl)-methanol
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
4-(Tert-butyldiphenylsilyloxy)methylbenzoic acid
1-[4-[4-(Acetyloxy)phenyl]-1-piperidinyl]ethanone